TC Biopharm (TCBP) Stock Price, News & Analysis

Company Overview

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Key Stats

• Today's Range: $0.50 to $1.54
• 50-Day Range: $0.68 to $0.68
• 52-Week Range: $0.50 to $160.00
• Volume: 5.33 million shs
• Average Volume: 177,918 shs
• Market Capitalization: $279.21 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.00
• Consensus Rating: Buy

TC Biopharm Stock Analysis - MarketRank™

TC Biopharm scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TC Biopharm has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TC Biopharm has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

TC Biopharm has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TCBP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TC Biopharm does not currently pay a dividend.

Dividend Growth

TC Biopharm does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TCBP.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added TC Biopharm to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TC Biopharm insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.44% of the stock of TC Biopharm is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.25% of the stock of TC Biopharm is held by institutions.

TCBP Stock Analysis - Frequently Asked Questions

When did TC Biopharm's stock split?

Shares of TC Biopharm reverse split on Monday, February 10th 2025.The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TC Biopharm IPO?

TC Biopharm (TCBP) raised $17 million in an initial public offering (IPO) on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO.

What other stocks do shareholders of TC Biopharm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), Exxon Mobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP).

Company Calendar

• Today: 8/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCBP
• CIK: 1872812
• Web: www.tcbiopharm.com
• Phone: 44-14-1433-7557
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TC Biopharm: $48.00
• High Price Target: $48.00
• Low Price Target: $48.00
• Potential Upside/Downside: +6,948.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.12
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.76 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $519.58 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 410,000
• Free Float: 28,000
• Market Cap: $279.21 thousand
• Optionable: Not Optionable
• Beta: 0.01